GSK Raises Outlook, Looks to New Medicines to Fuel Growth (3)

GSK Plc raised its guidance for the year after a strong start to 2023 as it prepares to begin selling one of the first vaccines to prevent a common respiratory virus.

Sales will increase by as much as 10% and earnings per share by as much as 17% this year, the UK drugmaker said in a statement Wednesday. The stock showed little change in London trading as analysts had anticipated the outlook upgrade.

Chief Executive Officer Emma Walmsley is attempting to prove GSK can go it alone as a pharma business after splitting from the consumer-products unit that made Centrum ...